ATE293996T1 - Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren - Google Patents

Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren

Info

Publication number
ATE293996T1
ATE293996T1 AT99951901T AT99951901T ATE293996T1 AT E293996 T1 ATE293996 T1 AT E293996T1 AT 99951901 T AT99951901 T AT 99951901T AT 99951901 T AT99951901 T AT 99951901T AT E293996 T1 ATE293996 T1 AT E293996T1
Authority
AT
Austria
Prior art keywords
diagnostic
polypeptide
protein
disulfide
peptide
Prior art date
Application number
AT99951901T
Other languages
English (en)
Inventor
William J Mcbride
Gary L Griffiths
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE293996T1 publication Critical patent/ATE293996T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT99951901T 1998-10-13 1999-10-13 Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren ATE293996T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10390498P 1998-10-13 1998-10-13
PCT/US1999/023614 WO2000021573A1 (en) 1998-10-13 1999-10-13 Site-specific labeling of disulfide-containing targeting vectors

Publications (1)

Publication Number Publication Date
ATE293996T1 true ATE293996T1 (de) 2005-05-15

Family

ID=22297637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99951901T ATE293996T1 (de) 1998-10-13 1999-10-13 Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren

Country Status (8)

Country Link
EP (1) EP1121153B1 (de)
JP (1) JP4680387B2 (de)
AT (1) ATE293996T1 (de)
AU (1) AU755783B2 (de)
CA (1) CA2346170C (de)
DE (1) DE69925009T2 (de)
ES (1) ES2242426T3 (de)
WO (1) WO2000021573A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287149A1 (de) * 2009-08-20 2011-02-23 Max-Delbrück-Centrum Für Molekulare Medizin Verstärker des Proteinabbaus
BR112015032200A2 (pt) 2013-06-24 2017-11-21 Hanwha Chemical Corp conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
ATE246009T1 (de) * 1995-06-07 2003-08-15 Immunomedics Inc Thiolierung von peptiden zur strahlendiagnostik und strahlentherapie auf radionuklidbasis

Also Published As

Publication number Publication date
DE69925009T2 (de) 2006-03-02
JP4680387B2 (ja) 2011-05-11
EP1121153A1 (de) 2001-08-08
CA2346170C (en) 2010-01-12
CA2346170A1 (en) 2000-04-20
AU6424499A (en) 2000-05-01
EP1121153B1 (de) 2005-04-27
WO2000021573A1 (en) 2000-04-20
AU755783B2 (en) 2002-12-19
ES2242426T3 (es) 2005-11-01
JP2002527409A (ja) 2002-08-27
DE69925009D1 (de) 2005-06-02

Similar Documents

Publication Publication Date Title
Südhof et al. Cassette of eight exons shared by genes for LDL receptor and EGF precursor
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
Gilliland et al. Chimeric toxins: toxic, disulfide-linked conjugate of concanavalin A with fragment A from diphtheria toxin
ATE353864T1 (de) Fluorierung von proteinen und peptiden für positronemissionstomographie
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
ATE204480T1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
Elovson Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins.
DE69632546D1 (de) Ob proteinderivate mit verlängerter halbwertzeit
Yu Studies on the pargyline-binding site of different types of monoamine oxidase
DK0765343T3 (da) Monoklonale antistoffer imod CD44v6
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
Watanabe et al. Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the α1 subunit of the skeletal muscle calcium channel
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
Veijola et al. Co-expression of the α subunit of human prolyl 4-hydroxylase with BiP polypeptide in insect cells leads to the formation of soluble and insoluble complexes. Soluble α-subunit-BiP complexes have no prolyl 4-hydroxylase activity
DK0948536T3 (da) G-protein-koblet receptor med et forstörret extracellulært domæne
PT85317A (fr) Procede pour l:obtention d:imunotoxines par couplage d:un anticorps avec une proteine trichosanthine ou trickokirine
ATE293996T1 (de) Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren
Boguslawski et al. Improved procedure for preparation of F (ab′) 2 fragments of mouse IgGs by papain digestion
Childs et al. Recombinant soluble human CD69 dimer produced in Escherichia coli: reevaluation of saccharide binding
ATE317021T1 (de) Antisense modulierung von lfa-3
ATE197709T1 (de) Methadonderivate und protein- und polypeptid- methadonkonjugate und markierte verbindungen
DE59505175D1 (de) Geformte, paraffinhaltige Mastiziermittel
Whitley et al. The DsbA-DsbB system affects the formation of disulfide bonds in periplasmic but not in intramembraneous protein domains

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties